Osama Hamdy is an Endocrinology/Metabolic physician affiliated with Joslin Diabetes Center. OpenAlex indexes 183 publications with 8,435 citations (h-index 40); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Joslin Pl
Boston, MA 022155306
Telephone
617-732-2400Registry record last updated 24 Feb 2011.
Clinical trials
- Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Sponsor: Joslin Diabetes Center
- Malaysia Diabetes Ramadan Nutrition Plan (My Dia-RNP®): A Feasibility Study
Sponsor: Universiti Putra Malaysia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20252 payments
- Inspire Medical Systems, Inc.Program year20251 payment
- Abbott LaboratoriesProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
77.6%GLP-1 receptor agonist23.8%Mounjaro42%Trulicity29%Ozempic28%Part D≥33 patientsInsulin Analog15.4%Tresiba Flextouch U-20027%Toujeo Solostar20%Lantus Solostar17%Basaglar Kwikpen U-1009%Tresiba Flextouch U-1008%Humalog Kwikpen U-1008%Admelog Solostar6%Apidra Solostar5%Part D<11 patients+ 5 more classes in this area
Cardiovascular
20.3%Statin11%Atorvastatin Calcium52%Rosuvastatin Calcium30%Simvastatin10%Pravastatin Sodium7%Part D<11 patientsACE inhibitor3.4%Lisinopril100%Part D≥17 patients+ 4 more classes in this area
Genitourinary & hormones
1%Androgen1%Testosterone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2008 per NIH RePORTER. The latest:
- EFFECT OF LONG TERM WEIGHT LOSS ON ENDOTHELIAL FUNCTION
Beth Israel Deaconess Medical Center
FY2008$1,126M01RR001032 - EFFECT OF LONG TERM WEIGHT LOSS ON ENDOTHELIAL FUNCTION
Beth Israel Deaconess Medical Center
FY2007$7,630M01RR001032 - EFFECT OF LONG TERM WEIGHT LOSS ON ENDOTHELIAL FUNCTION
Beth Israel Deaconess Medical Center
FY2006$9,049M01RR001032
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Lloyd Aiello, MD, PhD
Joslin Diabetes Center
Sylvia Rosas, MD
Joslin Diabetes Center
Jason Gaglia, MD
Joslin Diabetes Center
Mary Horlick
Joslin Diabetes Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”